0.83982.79% ( +0.0228 )
Closed: Oct 26, 16:00:01 (EDT)Current ValuationThe current P/E ratio is -0.19, within the reasonable range, cheaper than 33.33% of the time in the past 1 years, and the industry ranks 11/37, the industry Median -0.93.
-0.185xP/E
$0.84Stock price
$-4.53Earnings per share
-0.185xP/E
Stock price$0.84Earnings per share$-4.53
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.24x
- Typical range
- -0.34x–-0.15x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -41.87x | 74.45% | $4.96B |
SDGRUSSchrodinger | -33.73x | 16.60% | $1.83B |
CERTUSCertara | -23.66x | 2,116.80% | $1.62B |
TDOCUSTeladoc | -6.39x | 21.96% | $1.13B |
MDRXUSVeradigm | -- | -- | $808.86M |
SOPHUSSophia Genetics SA | -7.92x | 19.83% | $640.16M |
EVHUSEvolent Health | -1.00x | 84.41% | $512.16M |
CTEVUSClaritev | -1.29x | 12.62% | $365.05M |
AMWLUSAmerican Well | -2.95x | 57.74% | $230.30M |
DHUSDefinitive Healthcare | -0.93x | 28.60% | $156.43M |
HCATUSHealth Catalyst | -0.46x | 4.22% | $122.67M |
LFMDUSLifeMD | -34.51x | 195.82% | $100.26M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.34x | -- | $46.49M |
DRIOUSDarioHealth | -4.76x | 60.40% | $33.30M |
ONMDUSOneMedNet | -3.15x | -- | $26.50M |
ITOCUSiTonic | -2.08x | -- | $18.51M |
AIFFUSFirefly Neuroscience | -1.56x | -- | $14.75M |
BFRGUSBullfrog AI | -1.49x | 41.27% | $8.92M |
HCTIUSHealthcare Triangle | -0.36x | 93.28% | $6.06M |
HLYKUSHealthLynked Corp. | -1.45x | -- | $5.82M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
